ArticleJournal of neuro-oncology2025
Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeImmunotherapy and stereotactic radiosurgery (SRS) are frequently combined in the management of brain metastases from non-small cell lung cancer (NSCLC) and melanoma. However, concurrent SRS and dual immune-checkpoint inhibition (ICPI) elevate the risk for symptomatic radionecrosis. As optimal radionecrosis management in the setting of immunotherapy is unknown, we aimed to characterize our institutional approaches and outcomes in patients with biopsy-proven radionecrosis.
methodsPatients with NSCLC and melanoma brain metastases treated with SRS from 2014 to 2022 were identified from a prospective database. Only cases with biopsy-confirmed radionecrosis were included. The primary outcome was radiographic stabilization following treatment. Secondary outcomes included symptomatic resolution, overall survival, and cause of death.
resultsTwenty-five patients [14 women (56%); median age, 58 years; 15 NSCLC (60%), 10 melanoma (40%); median follow-up: 66 months] with 30 cases of necrosis met inclusion criteria. 84% of patients received immunotherapy and twenty-one (84%) were symptomatic. Twenty-three cases (77%) received prophylactic steroids during SRS. Median time from SRS to biopsy-confirmed radionecrosis was 9.3 (95%CI: 6.8-17.9) months. Thirty-two interventions were performed: 21 laser interstitial thermal therapy, seven resection, and four medical management. Estimated 6-month radiographic stabilization was 80% (95%CI: 59-90%). Median time to stabilization with dual, single, and no ICPI was 2.7 (95%CI: 1.4-NR), 1.2 (95%CI: 0.8-NR), and 0 (95%CI: 0-NR) months, respectively. Three (14%) and two (29%) CTCAE grade ≥ 3 adverse events occurred following LITT and resection, respectively, with no grade 5 events.
conclusionExisting radionecrosis management strategies appear effective in patients receiving immunotherapy, though prospective trials are needed for validation. TRIAL REGISTRATION NUMBER: N/A. DATE OF REGISTRATION: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.